Advanced Search

Newborn blood spot screening for galactosemia, tyrosiemia type I, homocystinuria,sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease and severe combined immunodeficiency

Alberta STE Report written under contract with the Alberta Health Technologies Decision Process (AHTDP).

This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting.

Section Authors:

  • Section One – Background and Context: Arianna Waye
  • Section Two – Social and System Demographics: Arianna Waye
  • Section Three – Technology Effectiveness and Safety: Mohamed El Shayeb, Bing Guo, Paula Corabian
  • Section Four – Economic Analysis: Charles Yan, Arianna Waye, Ilke Akpinar, Anderson Chuck
  • Section Five – Conclusion: Anderson Chuck, Arianna Waye
  • Information Specialist: Dagmara Chojecki

Publication Type: Health Technology Assessments /
Systematic Reviews

Year of Publication: 2016

Topics: Maternal and Child Health, Screening

Authors: IHE Institute of Health Economics

ISBN (online): 978-1-926929-65-1